The DOI matches its Crossref record; 17 of the 17 references it cites were found in a registry or an index.
Varenicline, Smoking Cessation, and Neuropsychiatric Adverse Events
Open accessAbstract
OBJECTIVE: In 2009, the U.S. Food and Drug Administration issued a black box warning for varenicline regarding neuropsychiatric events. The authors used data from randomized controlled trials and from a large Department of Defense (DOD) observational study to assess the efficacy and safety of varenicline. METHOD: The authors reanalyzed data from the 17 placebo-controlled randomized controlled trials (N=8,027) of varenicline conducted by Pfizer, using complete intent-to-treat person-level longitudinal data to assess smoking abstinence and reports of suicidal thoughts and behavior, depression, aggression/agitation, and nausea and to compare effects in patients with (N=1,004) and without (N=7,023) psychiatric disorders. The authors also analyzed a large DOD data set to compare acute (30-day and 60-day) rates of neuropsychiatric adverse events in patients receiving varenicline or nicotine replacement therapy (N=35,800) and to assess reports of anxiety, mood, and psychotic symptoms and disorders, other mental disorders, and suicide attempt. RESULTS: In the randomized controlled trials, varenicline increased the risk of nausea (odds ratio=3.69, 95% CI=3.03-4.48) but not rates of suicidal events, depression, or aggression/agitation. It significantly increased the abstinence rate, by 124% compared with placebo and 22% compared with bupropion. Having a current or past psychiatric illness increased the risk of neuropsychiatric events equally in treated and placebo patients. In the DOD study, after propensity score matching, the overall rate of neuropsychiatric disorders was significantly lower for varenicline than for nicotine replacement therapy (2.28% compared with 3.16%). CONCLUSIONS: This analysis revealed no evidence that varenicline is associated with adverse neuropsychiatric events. The evidence supports the superior efficacy of varenicline relative to both placebo and bupropion, indicating considerable benefit without evidence of risk of serious neuropsychiatric adverse events, in individuals with and without a recent history of a psychiatric disorder.
Overview
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
The cited source says what the claim attributes to it.
In the citing paper
“After propensity score matching, the overall rate of neuropsychiatric adverse events was significantly lower for varenicline than for NRT.”
From Are smoking cessation treatments associated with suicidality risk? An overview (2016) · cites this paper as [48]
The cited source says what the claim attributes to it.
In the citing paper
“Meta-analyses of randomized controlled trials to date have not supported a correlation between neuropsychiatric adverse events and use of varenicline.”
From Are smoking cessation treatments associated with suicidality risk? An overview (2016) · cites this paper as [48]
The cited source says what the claim attributes to it.
In the citing paper
“but not the rates of suicidal events, depression, or changes in behavior.”
From Are smoking cessation treatments associated with suicidality risk? An overview (2016) · cites this paper as [48]
The cited source says what the claim attributes to it.
In the citing paper
“A history of current or past psychiatric illness increased the risk of neuropsychiatric events equally in patients treated with varenicline and those receiving placebo.”
From Are smoking cessation treatments associated with suicidality risk? An overview (2016) · cites this paper as [48]
The cited source says what the claim attributes to it.
In the citing paper
“They found that varenicline increased the risk of nausea (OR 3.69, 95% CI 3.03–4.48)”
From Are smoking cessation treatments associated with suicidality risk? An overview (2016) · cites this paper as [48]
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
The central role of the propensity score in observational studies for causal effects
ROSENBAUM, P. R., & RUBIN, D. B. (1983) · Biometrika · doi:10.1093/biomet/70.1.41 · Cited by 31,241
Longitudinal Data Analysis for Discrete and Continuous Outcomes
Zeger, S. L., & Liang, K. (1986) · Biometrics · doi:10.2307/2531248 · Cited by 7,781
Dialysis Dose and Intradialytic Hypotension: Results from the HEMO Study
Causland, F. R. M., Brunelli, S. M., & Waikar, S. S. (2013) · American Journal of Nephrology · doi:10.1159/000355958 · Cited by 2,705
(2018) · Sage eBooks · doi:10.4135/9781506326139.n404 · Cited by 1,538
Nicotine receptor partial agonists for smoking cessation
Hey, K., Lancaster, T., & Bala, M. (2006) · Cochrane Database of Systematic Reviews · doi:10.1002/14651858.cd006103 · Cited by 866
Nicotine receptor partial agonists for smoking cessation
Cahill, K., Stead, L., & Lancaster, T. (2007) · Cochrane Database of Systematic Reviews · doi:10.1002/14651858.cd006103.pub2 · Cited by 747
Singer, B. H. (2005) · Encyclopedia of Statistical Sciences · doi:10.1002/0471667196.ess1502.pub3 · Cited by 251
Nicotine receptor partial agonists for smoking cessation (Review)
Cahill, K., Lf, S., & Lancaster, T. (2007) · Cited by 205
Gunnell, D., Irvine, D., Wise, L., Davies, C., & Martin, R. M. (2009) · BMJ · doi:10.1136/bmj.b3805 · Cited by 200
Suicidal Behavior and Depression in Smoking Cessation Treatments
Moore, T. J., Furberg, C. D., Glenmullen, J., Maltsberger, J. T., & Singh, S. (2011) · PLoS ONE · doi:10.1371/journal.pone.0027016 · Cited by 150
Tonstad, S., Davies, S., Flammer, M., Russ, C., & Hughes, J. (2010) · Drug Safety · doi:10.2165/11319180-000000000-00000 · Cited by 142
Cinciripini, P. M., Robinson, J. D., Karam-Hage, M., Minnix, J. A., Lam, C., Versace, F., Brown, V. L., Engelmann, J. M., & Wetter, D. W. (2013) · JAMA Psychiatry · doi:10.1001/jamapsychiatry.2013.678 · Cited by 136
A Preliminary Benefit-Risk Assessment of Varenicline in Smoking Cessation
Cahill, K., Stead, L. F., & Lancaster, T. (2009) · Drug Safety · doi:10.2165/00002018-200932020-00005 · Cited by 73
Kasliwal, R., Wilton, L. V., & Shakir, S. A. W. (2009) · Drug Safety · doi:10.2165/00002018-200932060-00006 · Cited by 71
Garza, D., Murphy, M. F., Tseng, L., Riordan, H., & Chatterjee, A. K. (2011) · Biological Psychiatry · doi:10.1016/j.biopsych.2010.12.005 · Cited by 50
Meyer, T. E., Taylor, L. G., Xie, S., Graham, D. J., Mosholder, A. D., Williams, J. R., Moeny, D. G., Ouellet‐Hellstrom, R., & Coster, T. S. (2012) · Addiction · doi:10.1111/j.1360-0443.2012.04024.x · Cited by 45
Strategies for Quantifying the Relationship between Medications and Suicidal Behaviour
Gibbons, R. D., & Mann, J. J. (2011) · Drug Safety · doi:10.2165/11589350-000000000-00000 · Cited by 44
Self-citation
Research works printed but not linked: 2
- Cahill K, 2012, Cochrane Database Syst Rev, 4, CD006103
- Hedeker D, 2008, SuperMix: A Program for Mixed-Effects Regression Models
Cited by
Sorted by citations
Anthenelli, R. M., Benowitz, N. L., West, R., St Aubin, L., McRae, T., Lawrence, D., Ascher, J., Russ, C., Krishen, A., & Evins, A. E. (2016) · The Lancet · doi:10.1016/s0140-6736(16)30272-0 · Cited by 1,177
Nicotine receptor partial agonists for smoking cessation
Cahill, K., Stead, L., & Lancaster, T. (2007) · Cochrane Database of Systematic Reviews · doi:10.1002/14651858.cd006103.pub2 · Cited by 747
Nicotine receptor partial agonists for smoking cessation
Cahill, K., Lindson-Hawley, N., Thomas, K. H., Fanshawe, T. R., & Lancaster, T. (2016) · Cochrane Database of Systematic Reviews · doi:10.1002/14651858.cd006103.pub7 · Cited by 433
Evins, A. E., Cather, C., Pratt, S. A., Pachas, G. N., Hoeppner, S. S., Goff, D. C., Achtyes, E. D., Ayer, D., & Schoenfeld, D. A. (2014) · JAMA · doi:10.1001/jama.2013.285113 · Cited by 207
Thomas, K. H., Martin, R. M., Knipe, D. W., Higgins, J. P. T., & Gunnell, D. (2015) · BMJ · doi:10.1136/bmj.h1109 · Cited by 155
Metadata
- Authors
- Gibbons, R. D., & Mann, J. J.
- Affiliations
- University of Chicago (US)
- Venue
- American Journal of Psychiatry
- Published
- 2013-12
- Volume
- 170
- Issue
- 12
- Pages
- 1460-1467
- ISSN
- 0002-953X (ISSN-L)
- 1535-7228
- PMC
- PMC4238282
- OpenAlex
- W2101931786
- Cited by
- 142
- References
- 17
- Citations by year
- 2026: 3 · 2024: 2 · 2023: 6 · 2021: 29 · 2020: 10 · 2019: 4 · 2018: 7 · 2017: 10 · 2016: 23 · 2015: 28 · 2014: 16 · 2013: 3
- FWCI
- 16.25
- Type
- journal article
- Language
- en
- Open access
- green
- www.ncbi.nlm.nih.gov
- Locations
- American Journal of Psychiatry (publishedVersion)
- PubMed (publishedVersion)
- Europe PMC (PubMed Central) (acceptedVersion)
- PubMed Central (acceptedVersion)
- Funders
- U.S. Department of Justice
- Pfizer
- National Institute of Mental Health (MH8012201, MH-062185, P50MH062185)
- Topics
- Health Sciences › Medicine › Public Health, Environmental and Occupational Health › Smoking Behavior and Cessation
- Life Sciences › Pharmacology, Toxicology and Pharmaceutics › Toxicology › Pharmacovigilance and Adverse Drug Reactions
- Health Sciences › Medicine › Epidemiology › Substance Abuse Treatment and Outcomes
- Keywords
- varenicline, smoking cessation, neuropsychiatric adverse effects, black box warning, nicotine replacement therapy, bupropion, smoking abstinence, suicidal ideation, depression, aggression, nausea, mental illness, military personnel, drug safety
- MeSH terms
- Varenicline, Adult, Aggression, Mental Disorders, Benzazepines, Depression, Female, Humans, Male, Nausea, Psychomotor Agitation, Quinoxalines, Risk Factors, Suicide, Attempted, Randomized Controlled Trials as Topic, Smoking Cessation, Bupropion, Treatment Outcome, Akathisia, Drug-Induced, Suicidal Ideation, Tobacco Use Cessation Devices, Observational Studies as Topic
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
